Improvement of Care & Outcome
People with T1D (PWDs) are at increased risk of all-cause mortality, especially cardiovascular mortality. Lipid and blood pressure (BP) management with lipid-lowering medication (LLM) and antihypertensive medication (AHM) plays an important role in cardiovascular disease (CVD) prevention. Many studies on CVD risk reduction have been in the context glycaemic control, rather than in the context of lipid and BP management, mainly in T2D. Studies assessing lipids and BP in PWDs have been done in the past, but both cardiometabolic risk management and glycaemic control have improved since then. This study, co-authored by Dick Mul and Henk-Jan Aanstoot of Diabeter, aimed to provide an update of lipid profiles and BP in various age groups and between men and women adult PWDs and to compare these to the general population.
This was a cross-sectional study including 2,287 PWDs from Diabeter and the UMCG and 146,822 people from the general population (Lifelines cohort). Age, sex, ethnicity, BMI, smoking behaviour, BP, total cholesterol, LDL-cholesterol, LLM use, AHM use and the presence of CVD were extracted from electronic health records.
Concluding, the authors state